Luspatercept  (Synonyms: ACE-536; luspatercept–aamt)

Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia^[1].

Human

Luspatercept (0.1-1000 ng/mL) 抑制 A204 细胞中 GDF11 和 GDF8 诱导的 Smad2 和 Smad 3 信号通路^[1]。
Luspatcept 与 GDF11，GDF8，activin B，BMP10 和 BMP6 结合^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Luspatercept (0.1-60mg /kg，皮下注射；10mg /kg，静脉注射；每周 2 次，共 8 周) 增加小鼠、大鼠和猴子的红细胞 (RBC) 数量、血红蛋白水平和红细胞堆积^[1]。
Luspatercept (10mg /kg，皮下注射，1 次) 降低 C57BL/6 小鼠骨髓和脾脏中的红细胞形成单位 (BFU-Es) 和红血球形成单位 (CFU-Es)^[1]。
Luspatercept (10mg /kg，腹腔注射，1 次) 抑制小鼠脾脏 Smad2/3 磷酸化^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1373715-00-4

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  [ACVR2B (activin A receptor type 2B, ActR-IIB, ActRIIB)]2-IGHG1 Fc (Fragment constant)

• 
  Immobilized Recombinant Anti-ACVR2B Antibody can bind Luspatercept. The EC₅₀ for this effect is 3.08 ng/mL.

• [1]. Suragani RN, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014 Apr;20(4):408-14.  [Content Brief]